Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 10,200 shares, a decline of 73.4% from the January 15th total of 38,400 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 103,600 shares, the days-to-cover ratio is currently 0.1 days.

Theratechnologies Price Performance

NASDAQ THTX traded up $0.02 on Thursday, hitting $1.64. 9,691 shares of the company were exchanged, compared to its average volume of 99,713. The firm has a market capitalization of $75.41 million, a P/E ratio of -16.40 and a beta of 1.26. The company’s 50 day moving average price is $1.69 and its 200-day moving average price is $1.42. Theratechnologies has a twelve month low of $1.08 and a twelve month high of $2.18.

Institutional Investors Weigh In On Theratechnologies

Several large investors have recently made changes to their positions in THTX. National Bank of Canada FI raised its stake in shares of Theratechnologies by 29.4% in the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after purchasing an additional 42,435 shares in the last quarter. Cyndeo Wealth Partners LLC boosted its holdings in Theratechnologies by 26.1% in the third quarter. Cyndeo Wealth Partners LLC now owns 131,311 shares of the company’s stock valued at $163,000 after acquiring an additional 27,191 shares during the last quarter. Harbour Investments Inc. lifted its stake in Theratechnologies by 20.0% in the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock valued at $159,000 after buying an additional 14,655 shares during the period. Wealthspire Advisors LLC raised its position in Theratechnologies by 39.0% in the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after buying an additional 20,000 shares during the last quarter. Finally, Hillsdale Investment Management Inc. bought a new position in Theratechnologies in the fourth quarter valued at approximately $108,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.